Recent updates focus on differences in biology that correlate with IDH status to delineate IDH mutant tumors (astrocytoma WHO Grade IV) vs IDH wild-type tumors (glioblastoma) [8, 9]. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).